Tyra Biosciences to Present at UBS Biotech Management Live Call Series on Achondroplasia and Growth Disorders.

Tyra Biosciences announced its participation in the UBS Biotech Management Live Call Series, where management will discuss achondroplasia and growth disorders in a virtual fireside chat. The event will take place on July 25, 2025, and will feature Todd Harris, CEO, Doug Warner, MD, CMO, and Alan Fuhrman, CFO, among others. The company's precision medicine platform, SNÅP, enables rapid drug design through molecular SNÅPshots that predict genetic alterations causing acquired resistance to existing therapies. Tyra Biosciences is focused on developing next-generation precision medicines targeting FGFR biology.